Sector News

Merck KGaA to build new life science hub in Massachusetts

July 20, 2016
Life sciences

Germany’s Merck KGaA has announced new plans to create a “major hub” for its North American life science business as it prepares to build a new campus in Burlington, MA, but will be leaving its former Billerica base.

The 280,000-square-foot facility (with an option to add an extra 70,000 square feet in the future) will cost around $115 million and should be up and ready by mid-2017. The facility will include a “customer collaboration” lab and training center, according to the company’s statement.

The new center will however see all 850 Billerica-based employees of MilliporeSigma, the U.S. unit of Merck, move into the facility–replacing its Billerica campus with what will be bigger and more “state-of-the-art” digs.

MilliporeSigma added however that it will maintain its other North American life science hub in St. Louis, Missouri.

“This new and more expansive MilliporeSigma campus gives us a unique, multiuse life science hub in the United States–one that provides our employees and customers with a sustainable and collaborative working environment,” said Udit Batra, CEO of MilliporeSigma, in the statement.

This campus will house what the company calls an “M Lab Collaboration Center,” which is essentially a shared space for its scientists and engineers work together with their life science customers.

The M Lab Collaboration Center will be one of 9 centers worldwide created specifically for collaboration, which includes training and customer experiments. Other locations will include Brazil, China, France, India, Singapore and South Korea, the biotech said.

“For nearly a decade, Merck KGaA has built a significant presence in Massachusetts and we are extremely pleased to support their expansion in Burlington through the MassWorks Infrastructure Program,” added Gov. Charlie Baker in the statement.

“Building long-lasting public-private partnerships is vital to growing our economy, and the MilliporeSigma campus represents significant investment and confidence in our shared future as a global life science center.”

Merck has a number of businesses and units which focus on manufacturing, biosimilars, consumer health and life science R&D. The company has recently been ramping up its R&D focus, with a near $900 million deal struck with Pfizer a few years back to further development of its checkpoint inhibitor candidate.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.